Journal of Clinical Oncology
Articles in this Issue
Efficacy and safety of retifanlimab across solid tumors: A systematic review and meta-analysis.
e14585 Background: Retifanlimab is a PD-1 inhibitor with demonstrated activity in several solid tumors, including FDA appr...
Distinct T-cell subsets as drivers of response to different neoadjuvant treatments in esophageal squamous cell carcinoma.
2638 Background: The optimal integration of immunotherapy with chemoradiotherapy (CRT) in the neoadjuvant treatment of eso...
A retrospective analysis of patients with metastatic melanoma treated with sequential metronomic temozolomide after immune therapy failure.
e21515 Background: Melanoma is a skin malignancy that results in the deaths of around 60,000 people globally per year. Alt...
Digital twin survival calibration to enable cross-disease interpretation of early clinical trials.
e14507 Background: Early-phase oncology programs increasingly explore multiple disease indications, yet overall survival o...
Elevated red blood cell distribution width-to-albumin ratio and incident cancer risk: A prospective cohort study.
10575 Background: Cancer remains a leading cause of global morbidity and mortality, underscoring the need for accessible b...
Efficacy and safety of primary thromboprophylaxis in adult ambulatory cancer patients: A scholarly review.
e24003 Background: Venous thromboembolism (VTE) is a major complication in patients with cancer, with approximately a six-...
Scanxiety: Patient experience of immediate result release (IRR) of cancer-related imaging.
e13583 Background: The 21 st Century Cures Act, signed in 2016, requires immediate...
OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy with regulatable membrane-bound IL15 (mbIL15) in patients with advanced melanoma that has progressed on/after immune checkpoint inhibitors (ICI): Phase 2 results.
9507 Background: OBX-115 TIL are engineered to express mbIL15 under regulatory control of the small-molecule drug acetazol...
Precision Promise (PrP): Success rates of paired biopsies and biomarker testing results for metastatic pancreatic cancer (mPDAC) in a multi-center trial.
4196 Background: PrP, a phase 2/3 Bayesian adaptive platform trial sponsored by the Pancreatic Cancer Action Network, was...
Results from a phase 2a study of atebimetinib in combination with mGnP in advanced or metastatic pancreatic cancer.
4013 Background: Pancreatic ductal adenocarcinoma (PDAC) is driven predominantly by oncogenic KRAS signaling, yet prior at...
Stage I results of a phase II study evaluating thymosin α1 combined with toripalimab in elderly patients with advanced melanoma.
9554 Background: Anti–PD-1 monotherapy yields limited response rates in Chinese patients with melanoma, highlighting the n...
Dynamic biological and metabolic response by EBV DNA and <sup>18</sup> F-FDG-PET-CT to induction chemotherapy (IC) to enhance prognostication in endemic nasopharyngeal carcinoma (NPC).
6112 Background: IC followed by concurrent chemoradiotherapy (CCRT) is the current standard of care for locoregionally-adv...
Don't smoke the odds: Improving lung cancer screening among current smokers in East Texas.
e23286 Background: Lung cancer has been the leading cause of cancer death in the United States for over 70 years. Approxim...
Screen failures among patients who consented for early phase cancer clinical trials (EPCTs).
e23013 Background: EPCTs represent an important treatment option for patients with cancer. However, trials often have stri...
Comparing the rates of hypersensitivity reactions in patients undergoing first-dose taxanes utilizing fixed-rate vs. stepwise-titration infusions.
e24165 Background: Taxanes are associated with a higher incidence of immediate hypersensitivity reactions (HSRs) compared...
A phase Ia/Ib trial of FAP-Dox (AVA6000), a fibroblast activation protein (FAP)–released doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors and activity against salivary gland cancers.
e15113 Background: Faridoxorubicin (faridox, AVA6000) is a cleavable peptide drug conjugate (PDC) comprised of doxorubicin...
Real-world overall survival after PD-1 failure in advanced cutaneous squamous cell carcinoma.
e21570 Background: Anti–PD-1 therapy Cemiplimab is standard first-line systemic treatment for advanced cutaneous squamous...
Proteomics-based phosphorylated AKT S473 and PI3K/AKT inhibitors in patients with hormone receptor–positive (HR+) metastatic breast cancer (MBC).
e13053 Background: Multiple PIK3CA/AKT/mTOR (PAM) pathway inhibitors have been FDA-approved for HR+ MBC with PIK3CA mutati...
First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option: Additional efficacy endpoints from the TROPION-Breast02 study.
1002 Background: In the primary analysis of the phase 3 TROPION-Breast02 study (NCT05374512), first-line Dato-DXd demonstr...
Development of a computational histology artificial intelligence (CHAI)–powered predictive biomarker for first-line chemotherapy intensification in metastatic colorectal cancer (mCRC) and validation in prospective randomized phase III trials (RCT).
3513 Background: In unresectable mCRC, meta-analysis of RCTs suggests triplet therapy consisting of fluorouracil, oxalipla...
Changes in immunocompetent blood cells in patients with recurrent ovarian cancer depending on platinum sensitivity.
e17550 Background: Despite surgery and adjuvant chemotherapy, up to 80% of patients with ovarian cancer (OC) experience re...
Financial toxicity identified by COST–FACIT screening in a community oncology population: A retrospective study.
e23103 Background: Financial toxicity (FT) is common among patients receiving cancer treatment and is associated with adve...
Can we be one step ahead?: A systematic review and meta-analysis on the clinical prowess of artificial intelligence (AI) in predicting the malignant potential of pancreatic cysts.
e16008 Background: Population imaging studies show that pancreatic cystic lesions (PCLs)occur in about 2.5% of asymptomati...
Direct oral anticoagulants versus low-molecular-weight heparin in patients with liver metastases and cancer-associated thrombosis: A multi-center real-world analysis.
11179 Background: Patients with liver metastases are at high risk for cancer-associated thrombosis (CAT) and require thera...
Liposomal irinotecan plus sintilimab and lenvatinib for second-line advanced HER2-negative gastric/gastro-esophageal junction adenocarcinoma: A phase II trial.
e16035 Background: Effective second-line treatment options are limited for advanced gastric/gastro-esophageal junction (G/...